Benazepril (CAS 86541-75-5) is a second-generation angiotensin-converting enzyme (ACE) inhibitor widely used to treat hypertension, heart failure and related cardiovascular conditions. It is a prodrug, converted in vivo to its active metabolite benazeprilat, which inhibits ACE and reduces the formation of angiotensin II, leading to vasodilation and decreased blood pressure. Because of its efficacy and once-daily dosing potential, Benazepril remains an important component of many antihypertensive regimens.
Benazepril (86541-75-5) from TCS GROUP is supplied as a high-purity API suitable for oral solid dosage forms, including standard tablets and fixed-dose combinations. Its pharmacological profile—potent ACE inhibition, favorable duration of action and good tolerability in many patients—has supported its long-term use in both human and veterinary medicine.
In formulation, Benazepril’s properties require careful selection of excipients to ensure stability and robust dissolution. Stability considerations include control of moisture, protection from excessive heat and the use of appropriate packaging. Many manufacturers opt for tried-and-tested direct-compression systems where Microcrystalline Cellulose – Premium Filler & Binder for Direct Compression plays a central role in ensuring tablet strength and uniformity. Disintegrants and lubricants are then selected to achieve rapid, reliable disintegration without compromising compressibility.
Within a broader cardiovascular portfolio, Benazepril is frequently positioned alongside other APIs sourced from TCS GROUP. Beta-blockers such as Atenolol (29122-68-7) and anti-arrhythmic agents like Amiodarone Hydrochloride (19774-82-4) allow companies to offer comprehensive treatment options covering hypertension, arrhythmias and heart failure. Leveraging a single, trusted API partner helps streamline audits, documentation management and overall supply-chain complexity.
TCS GROUP supports Benazepril customers with full technical dossiers, regulatory documentation and application guidance, from early development through scale-up and commercial production. By combining reliable quality, consistent supply and experienced technical support, TCS GROUP enables manufacturers to bring Benazepril-based cardiovascular medicines to market efficiently while maintaining high standards of safety and efficacy.